


501-3292 Production Way, Burnaby, B.C., V5A 4R4 Phone: (604) 551-7831 Fax: 604-676-2767


> info@cannabixtechnologies.com cannabixtechnologies.com

Cannabix Technologies Provides Technology Update on Marijuana Breathalyzer Development

The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety.

Vancouver, British Columbia, August 27, 2018 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix") developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that characterization work has demonstrated the ability to isolate Δ9-tetrahydrocannabinol ("THC") and suppress background substrates effectively. Cannabix is developing an innovative FAIMS (field asymmetric waveform ion mobility spectrometry) based instrument for the detection of THC. Using the gold standard of mass spectrometry in tandem with the Cannabix FAIMS prototype device, Graph A and B below show suppression of background matrix allowing the *THC peak* to be easily recognized. This demonstrates the capability of the FAIMS device to isolate and detect THC from complex background matrix. The characterization work has been conducted using a bench version of the FAIMS device. Cannabix scientists have been actively tuning the FAIMS device coupled to real time switchable mass spectrometry to detect key molecules and their complex pathways in the body to enable the identification of recency of use.





The Company also reports that it has commenced identification of medical device manufacturers in order to implement human factor design (single or dual stage design), verification testing, and develop manufacturing documentation for standardization requirements, as well as create multiple devices for pilot testing.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

"Rav Mlait"

CEO

Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in

the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.